Security
Microbot Medical Inc. Common Stock · MBOT
MBOTNASDAQCommon stockCurrentCIK 883975Updated Oct 7, 2026
Name history
Microbot Medical Inc. · through Oct 6, 2026STEMCELLS INC · through Nov 15, 2016CYTOTHERAPEUTICS INC/DE · through May 15, 2000
MBOT price & chart
Loading TradingView…
NASDAQ:MBOT on TradingView ↗About the company
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. Further information about Microbot Medical® is available at http://www.microbotmedical.com.
In the news
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 1.01, 5.02, 9.01
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 81,544,000Source | 6,031,000Source | 8,327,000Source | 9,537,000Source |
| Property, Plant and Equipment, NetUSD | 93,000Source | 80,000Source | 146,000Source | 221,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,912,000Source | 3,114,000Source | 2,468,000Source | 2,442,000Source |
| Inventory, NetUSD | 584,000Source | — | — | — |
| Assets, CurrentUSD | 79,822,000Source | 5,819,000Source | 7,921,000Source | 8,814,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 644,000Source | 300,000Source | 152,000Source | 532,000Source |
| Operating Lease, Right-of-Use AssetUSD | 833,000Source | 132,000Source | 260,000Source | 502,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,990,000Source | 2,501,000Source | 3,826,000Source | 2,248,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 672,000Source | 195,000Source | 118,000Source | 80,000Source |
| Retained Earnings (Accumulated Deficit)USD | -104,086,000Source | -90,944,000Source | -79,501,000Source | -68,761,000Source |
| Stockholders' Equity Attributable to ParentUSD | 77,554,000Source | 3,530,000Source | 4,501,000Source | 7,289,000Source |
| Additional Paid in Capital, Common StockUSD | 180,968,000Source | 94,279,000Source | 83,884,000Source | 75,970,000Source |
| Liabilities and EquityUSD | 81,544,000Source | 6,031,000Source | 8,327,000Source | 9,537,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,421,000Source | 2,460,000Source | 3,786,000Source | 2,069,000Source |
| Operating Lease, Liability, CurrentUSD | 296,000Source | 70,000Source | 191,000Source | 283,000Source |
| Accounts Payable, CurrentUSD | 511,000Source | — | — | 116,000Source |
| Operating Lease, Liability, NoncurrentUSD | 569,000Source | 41,000Source | 40,000Source | 179,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,614,000Source | 2,225,000Source | 1,027,000Source | 1,670,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 78,592,000Source | 5,470,000Source | 6,385,000Source | 8,202,000Source |
| Deferred Tax Liabilities, NetUSD | 191,000Source | 30,000Source | 357,000Source | 114,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 47,000Source | 91,000Source | 106,000Source | 102,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,057,000Source | 1,349,000Source | 1,394,000Source | 1,752,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 584,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -13,046,000Source | -8,827,000Source | -8,533,000Source | -11,549,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -72,384,000Source | 1,537,000Source | 1,973,000Source | -3,836,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | -3,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 60,000Source | 25,000Source | 33,000Source | 84,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 86,240,000Source | 7,936,000Source | 6,558,000Source | 4,324,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 810,000Source | 646,000Source | -2,000Source | -11,061,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 171,000Source | 130,000Source | 51,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 1,752,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 78,592,000Source | 5,470,000Source | 6,385,000Source | 8,202,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | -2,000Source | -5,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | -1,111,000Source | — |
| General and Administrative ExpenseUSD | — | 4,995,000Source | 4,131,000Source | 5,545,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | 4,000Source | 0Source | 59,000Source | 12,000Source |
| Net Income (Loss) Attributable to ParentUSD | -13,142,000Source | -11,443,000Source | -10,740,000Source | -13,168,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | -5,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | 8,460,000Source | — | — | — |
| Operating Income (Loss)USD | -14,743,000Source | -11,625,000Source | -9,855,000Source | -13,281,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | -5,000Source |
| Net Income (Loss) Attributable to ParentUSD | -13,142,000Source | -11,443,000Source | -10,740,000Source | -13,168,000Source |
| Earnings Per Share, BasicUSD per share | -0.29Source | -0.73Source | -1.05Source | -1.81Source |
| Earnings Per Share, DilutedUSD per share | -0.29Source | -0.73Source | -1.05Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 45,790,362Source | 15,644,511Source | 10,199,984Source | 7,260,344Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 45,790,362Source | 15,644,511Source | 10,199,984Source | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | — | — | — | 4,562,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | -1,111,000Source | — |
| General and Administrative ExpenseUSD | — | 4,995,000Source | 4,131,000Source | 5,545,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 1,285,000Source | 182,000Source | 228,000Source | 118,000Source |
| Labor and Related ExpenseUSD | — | — | — | 2,067,000Source |
| Other ExpensesUSD | — | 239,000Source | — | — |
| Research and Development ExpenseUSD | 6,283,000Source | 6,630,000Source | 5,724,000Source | 7,736,000Source |
Offerings
Registration 333-284688
Filing attachments
ex99-1.htm · 8-K · 2026-10-06
Exhibit 99.1 Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S. HINGHAM, Mass., October 6, 2026 -- Microbot Medi…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter Revenue increased by more than 100% over prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April. The Company added new customers in Q3 while expanding into new states and sites of service. HINGHAM, Mass., August 11, 2026 -…
Read attachment ↗ex99-1.htm · 8-K · 2026-07-21
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting Company CEO has been a featured presenter at several recent industry events on the emergence of endovascular robotics as expert speaking opportunities raising profile of the Company throughout medtech market HINGHAM, Mass., July 21, 2026 - Microbot Medical Inc. (Nasdaq: MBOT), developer …
Read attachment ↗ex99-1.htm · 8-K · 2026-07-07
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume also Rises in the Second Quarter of 2026 The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets …
Read attachment ↗ex99-1.htm · 8-K · 2026-06-30
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader Expanding manufacturing capabilities is part of the Company’s cost reduction strategy and supports global expansion HINGHAM, Mass., June 30, 2026 - Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered int…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-25
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System Innovative Start-Up award recognizes LIBERTY as a highly innovative, ground-breaking product with potentially wide range and/or substantial benefit HINGHAM, Mass., June 25, 2026 - Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has won the Innovative Start-Up …
Read attachment ↗